On the other hand, cells with inactivated KLHL14, a negative BCR component regulator often mutated in DLBCL, induce the NFκB pathway by activating the MYD88-TLR9-BCR super-complex, which partially protects them from ibrutinib-induced cell death (91). This evidence concerns the gene KLHL14 and diffuse large B-cell lymphoma.